A Phase 4 interventional study of Greater occipital nerve block with bupivacaine and Metoclopramide in Migraine, sponsored by Montefiore Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-22.
Sponsored by Montefiore Medical Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Migraine Disorders by Montefiore Medical Center — none open to participants now, none under way, none of them phase 3. Migraine Disorders · Montefiore Medical Center.
Among the 15 studies in Migraine Disorders by Montefiore Medical Center, this one is the 10th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2017, is one of 9 in phase 4, and was the 13th registered.
1,657 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →None of the 15 studies in Migraine Disorders by Montefiore Medical Center is open now. The open studies under Migraine Disorders, anywhere →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 207 across the 14 interventional studies, 477 across the 1 observational. Of the 15 that completed or were terminated, 12 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Montefiore Medical Center is the lead sponsor of 416 studies on the registry; 69 are open to participants now.
Of its 88 completed or terminated interventional studies of FDA-regulated products, 76 (86%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Migraine Disorders by Montefiore Medical Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
We are comparing a type of nerve block called greater occipital nerve block versus standard therapy among patients who present to an emergency department for acute migraine. This is a randomized, double-blind, double dummy study. The greater occipital nerve block will be performed bilaterally with bupivacaine 0.5%. Standard therapy is metoclopramide 10mg IV.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Eligible patients are adults who present with an acute moderate or severe headache meeting migraine headache criteria, as defined by the International Classification of Headache Disorders-3β (1.1, migraine without aura). Patients who meet criteria for Probable Migraine without Aura (1.5.1) will also be included, provided they have had at least one similar attack previously.
Exclusion Criteria:
Patients will be excluded if cannot be obtained, if there is concern for a secondary cause of headache, if the maximum documented temperature is greater than 100.3 degrees, for a new objective neurologic abnormality, skull defect, suspected infection overlying injection site, known bleeding disorder, ongoing use of anti- agents including P2Y12 platelet inhibitors (clopidogrel, prasugrel, ticagrelor), heparins, warfarin, or 10a inhibitors (rivaroxaban, apixaban, edoxaban, fondaparinux), prior treatment with a greater occipital nerve block, allergy to the medications, pheochromocytoma, seizure disorder, Parkinson's disease, use of MAO inhibitors, and use of anti-rejection transplant medications.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilateral greater occipital nerve block with bupivacaine 0.5% + Normal saline IV
Procedure: Greater occipital nerve block with bupivacaine
Metoclopramide 10mg IV + Bilateral greater occipital nerve block with normal saline
Drug: Metoclopramide
This is a type of peripheral nerve block. 3cc of 0.5% bupivacaine will be injected adjacent to the greater occipital nerve block blaterally
Metoclopramide 10mg IV will be administered over 15 minutes
0-10 Pain Score
Pain score assessed at baseline and one hour. 0= no pain, 10 = worst imaginable. This outcome is the change in pain between baseline and one hour
Time frame: one hour
Sustained Headache Relief
Headache level = mild or none. Achieved in emergency department and maintained for 48 hours without rescue medication
Time frame: 48 hours
Sustained Headache Freedom
Headache = none, achieved in emergency department and maintained for 48 hours
Time frame: 48 hours
| Milestone | Greater Occipital Nerve Block | Metoclopramide |
|---|---|---|
| Started | 51 | 48 |
| Completed | 51 | 48 |
| Not completed | 0 | 0 |
Pain score assessed at baseline and one hour. 0= no pain, 10 = worst imaginable. This outcome is the change in pain between baseline and one hour
| units on a scale | Greater Occipital Nerve Block | Metoclopramide |
|---|---|---|
| 0-10 Pain Score | 5.0 (4.1 to 5.8) | 6.1 (5.2 to 6.9) |
Headache level = mild or none. Achieved in emergency department and maintained for 48 hours without rescue medication
| Participants | Greater Occipital Nerve Block | Metoclopramide |
|---|---|---|
| Sustained Headache Relief | 11 | 18 |
Headache = none, achieved in emergency department and maintained for 48 hours
| Participants | Greater Occipital Nerve Block | Metoclopramide |
|---|---|---|
| Sustained Headache Freedom | 3 | 7 |
Collected over 48 hours. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Greater Occipital Nerve Block | 0/51 (0%) | 0/51 (0%) | 16/51 (31.4%) |
| Metoclopramide | 0/48 (0%) | 0/48 (0%) | 18/48 (37.5%) |
| Event | Greater Occipital Nerve Block | Metoclopramide |
|---|---|---|
| VariousInvestigations | 1/51 | 9/48 |
| DizzinessNervous system disorders | 4/51 | 3/48 |
| head numbnessInjury, poisoning and procedural complications | 4/51 | 0/48 |
| drowsinessNervous system disorders | 0/51 | 3/48 |
| headacheNervous system disorders | 3/51 | 2/48 |
| Injection site reactionInjury, poisoning and procedural complications | 2/51 | 1/48 |
| Gastrointestinal symptomsGastrointestinal disorders | 2/51 | 0/48 |
| Age, Continuous(years) | Greater Occipital Nerve Block | Metoclopramide | Total |
|---|---|---|---|
| Mean | 39 ± 11 | 38 ± 11 | 39 ± 11 |
| Sex: Female, Male(Participants) | Greater Occipital Nerve Block | Metoclopramide | Total |
|---|---|---|---|
| Female | 44 | 34 | 78 |
| Male | 7 | 14 | 21 |
| Race and Ethnicity Not Collected(Participants) | Greater Occipital Nerve Block | Metoclopramide | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Greater Occipital Nerve Block | Metoclopramide | Total |
|---|---|---|---|
| United States | 51 | 48 | 99 |
| Baseline pain intensity(Participants) | Greater Occipital Nerve Block | Metoclopramide | Total |
|---|---|---|---|
| Severe pain | 38 | 35 | 73 |
| Moderate pain | 13 | 13 | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2017 to primary completion in Mar 2020, 28 months.
Results were first posted in Sep 2021, 1 year 6 months after primary completion.
Of 49 non-industry phase 4 interventional studies under Migraine Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's 28 months is close to that.
Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.